Envestnet Asset Management Inc. Buys 15,227 Shares of Insmed Incorporated (NASDAQ:INSM)

Envestnet Asset Management Inc. lifted its position in shares of Insmed Incorporated (NASDAQ:INSM) by 6.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 256,358 shares of the biopharmaceutical company’s stock after buying an additional 15,227 shares during the period. Envestnet Asset Management Inc. owned about 0.14% of Insmed worth $17,699,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. raised its stake in shares of Insmed by 6.3% during the 4th quarter. Vanguard Group Inc. now owns 18,218,973 shares of the biopharmaceutical company’s stock worth $1,257,838,000 after purchasing an additional 1,075,796 shares in the last quarter. Geode Capital Management LLC increased its position in Insmed by 7.2% during the fourth quarter. Geode Capital Management LLC now owns 4,087,143 shares of the biopharmaceutical company’s stock worth $282,243,000 after acquiring an additional 273,759 shares during the period. Artisan Partners Limited Partnership raised its position in shares of Insmed by 8.4% in the fourth quarter. Artisan Partners Limited Partnership now owns 3,126,339 shares of the biopharmaceutical company’s stock valued at $215,842,000 after buying an additional 242,242 shares in the last quarter. William Blair Investment Management LLC lifted its position in shares of Insmed by 0.5% during the 4th quarter. William Blair Investment Management LLC now owns 2,433,443 shares of the biopharmaceutical company’s stock valued at $168,005,000 after acquiring an additional 12,535 shares during the period. Finally, Pictet Asset Management Holding SA grew its holdings in shares of Insmed by 5.2% during the 4th quarter. Pictet Asset Management Holding SA now owns 1,959,718 shares of the biopharmaceutical company’s stock worth $135,299,000 after purchasing an additional 96,377 shares in the last quarter.

Insmed Price Performance

INSM stock opened at $71.07 on Wednesday. The company has a fifty day moving average price of $75.79 and a 200-day moving average price of $73.62. Insmed Incorporated has a 52-week low of $21.92 and a 52-week high of $84.91. The company has a market capitalization of $12.92 billion, a P/E ratio of -12.71 and a beta of 1.07. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The firm had revenue of $104.44 million for the quarter, compared to the consensus estimate of $102.31 million. As a group, equities analysts expect that Insmed Incorporated will post -4.56 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. Guggenheim reaffirmed a “buy” rating and issued a $101.00 price target on shares of Insmed in a research note on Tuesday, February 25th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Insmed in a report on Wednesday, February 19th. Bank of America lifted their price objective on shares of Insmed from $92.00 to $96.00 and gave the company a “buy” rating in a research note on Thursday, March 20th. Truist Financial upped their target price on Insmed from $105.00 to $108.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Finally, Wells Fargo & Company upped their price objective on Insmed from $85.00 to $107.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 19th. One equities research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $94.00.

Insider Buying and Selling at Insmed

In other Insmed news, insider Martina M.D. Flammer sold 33,055 shares of the firm’s stock in a transaction dated Thursday, February 6th. The stock was sold at an average price of $80.90, for a total value of $2,674,149.50. Following the completion of the transaction, the insider now owns 138,053 shares in the company, valued at $11,168,487.70. This trade represents a 19.32 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO William Lewis sold 18,750 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $81.03, for a total value of $1,519,312.50. Following the sale, the chief executive officer now owns 334,186 shares in the company, valued at $27,079,091.58. The trade was a 5.31 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 464,967 shares of company stock worth $37,142,046. 3.00% of the stock is owned by corporate insiders.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.